Major depressive episode

New Research Demonstrates Significant Benefit of Meru Health Program even for Patients with Severe Depressive Symptoms

Retrieved on: 
Monday, July 12, 2021
Mind, Psychology, Psychiatry, Psychiatric diagnosis, PHQ-9, Depression, Major depressive disorder, Mental health, Major depressive episode

In the study, Meru Health examined whether 218 patients with at least moderately severe depressive symptoms experienced reductions in depressive symptoms after participation in a therapist-supported, evidence-based mobile health intervention, the Meru Health Program.

Key Points: 
  • In the study, Meru Health examined whether 218 patients with at least moderately severe depressive symptoms experienced reductions in depressive symptoms after participation in a therapist-supported, evidence-based mobile health intervention, the Meru Health Program.
  • Patients with moderately severe and severe depressive symptoms at pre-program assessment experienced significant decreases in depressive symptoms at end-of treatment.
  • Also, 34% of patients with at least moderately severe depressive symptoms at baseline and 29.9% of patients with severe depressive symptoms at baseline responded, as defined by a 50% reduction in symptoms plus an end PHQ-9 score lower than 10 on the commonly used PHQ-9 scale (the cutoff for clinical levels of depression).
  • Meru Health partners with major health insurance providers like Cigna, Humana and Moda Health, as well as leading businesses who want to provide best-in-class mental health care for their employees or members.

Global Major Depressive Disorder Markets, Epidemiology and Patient Flow Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 13, 2021
Managed care, Health, Psychiatric diagnosis, Mood disorders, Psychiatry, Abnormal psychology, Major depressive disorder, Mind, Medicine, Depression, Disease, Depressive, Major depressive episode

b'The "Global Major Depressive Disorder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Major Depressive Disorder Epidemiology and Patient Flow Analysis - 2021, provides Major Depressive Disorder epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Major Depressive Disorder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Major Depressive Disorder Epidemiology and Patient Flow Analysis - 2021, provides Major Depressive Disorder epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Major Depressive Disorder patients, history of the disease at the population level (Major Depressive Disorder prevalence, Major Depressive Disorder incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nMajor Depressive Disorder patient flow: Major Depressive Disorder prevalence, diagnosed, and drug-treated patients\nDemographics: Major Depressive Disorder patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Major Depressive Disorder market sizing, assessing market potential, and developing drug forecast models\nIdentify Major Depressive Disorder patients segments through age groups, gender, and disease sub-types\nEvaluate Major Depressive Disorder market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210513005449/en/\n'

Janssen Seeks Expanded Use of SPRAVATO®▼ (Esketamine) Nasal Spray in Europe as a Treatment for Depressive Symptoms in Adults with Major Depressive Disorder Who Have Current Suicidal Ideation with Intent

Retrieved on: 
Wednesday, January 15, 2020
Pharmaceutical, Health, Mental health, Medical devices, Psychoactive drugs, Depression, Drugs, Antidepressants, Mood disorders, Psychiatric diagnosis, Amines, Esketamine, Janssen Pharmaceutica, Major depressive disorder, Major depressive episode, Suicidal ideation, SPRAVATO®▼, Major Depressive Disorder, the Janssen Pharmaceutical Companies of Johnson & Johnson

The application seeks to expand the use of esketamine nasal spray, beyond its current indication, as an acute short-term treatment, co-administered with oral antidepressant therapy, for the rapid reduction of depressive symptoms in adults with a moderate-to-severe depressive episode of major depressive disorder (MDD) who have current suicidal ideation with intent.

Key Points: 
  • The application seeks to expand the use of esketamine nasal spray, beyond its current indication, as an acute short-term treatment, co-administered with oral antidepressant therapy, for the rapid reduction of depressive symptoms in adults with a moderate-to-severe depressive episode of major depressive disorder (MDD) who have current suicidal ideation with intent.
  • While currently available antidepressants are effective in treating depressive symptomatology, they can often take weeks to achieve their full effects.
  • SPRAVATO (esketamine) nasal spray offers the first new mechanism of action in 30 years to treat major depressive disorder (MDD).5,6
    Esketamine nasal spray is self-administered through a single-use nasal spray device, offering a novel mode of drug administration for the treatment of MDD.
  • Janssen Research & Development, LLC and Janssen-Cilag International NV are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

The Days Are Getting Darker, but FEBC's Benefits May Help Members Who Are Feeling SAD

Retrieved on: 
Friday, October 26, 2018
Psychiatric diagnosis, Psychiatry, Depression, Mood disorders, Psychology, Emotions, Abnormal psychology, Major depressive disorder, Major depressive episode, Depressive, Sadness, Mood

For some, this time of the year may be harder for other reasons, namely a downward spiral in mood.

Key Points: 
  • For some, this time of the year may be harder for other reasons, namely a downward spiral in mood.
  • Some people may experience depressive episodes in the summer months (known as Reverse SAD), but it's far less common.
  • Financial Education Benefits Center (FEBC), a health and wellness membership company, offers several discounts to services which may help those who find themselves feeling the blues in the autumn and winter.
  • People with a genetic component of depression are much more likely to experience SAD than those who have no family history.